ARCH Venture Management, LLC reported 17 holdings worth US$1.61B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
ARCH Venture Management, LLC reported 17 holdings worth US$1.61B as of Sep 30, 2026. Largest: Kardigan, Inc., Parabilis Medicines, Inc. and Vir Biotechnology, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 17
- Value as reported
- US$1.61B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Kardigan, Inc. | 15M | US$222M | 13.8% |
| Parabilis Medicines, Inc. | 6.41M | US$207M | 12.8% |
| Vir Biotechnology, Inc. | 12.7M | US$142M | 8.8% |
| Sana Biotechnology, Inc. | 45.9M | US$134M | 8.3% |
| Seaport Therapeutics, Inc. | 6.29M | US$127M | 7.9% |
| Rapport Therapeutics, Inc. | 3.73M | US$125M | 7.8% |
| Scholar Rock Holding Corporation | 2.35M | US$113M | 7.0% |
| Maze Therapeutics, Inc. | 4.12M | US$112M | 6.9% |
| Beam Therapeutics Inc. | 4.54M | US$111M | 6.9% |
| Erasca, Inc. | 7.09M | US$104M | 6.4% |
| 908 Devices Inc. | 5.73M | US$70.6M | 4.4% |
| Prime Medicine, Inc. | 18.5M | US$56.5M | 3.5% |
| Lyell Immunopharma, Inc. | 3.25M | US$31.8M | 2.0% |
| Generate Biomedicines, Inc. | 1.94M | US$29.2M | 1.8% |
| Neumora Therapeutics, Inc. | 33.8M | US$20.2M | 1.3% |
| Boundless Bio, Inc. | 2.69M | US$6.76M | 0.42% |
| 10x Genomics, Inc. | 0 | US$0 | 0.00% |
| Gossamer Bio, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC